Paper39558776
Are we there yet? CAR-T therapy in multiple myeloma.
Mirvis E and 1 other. Br J Haematol, 2024. Cited by 5 papers, by iCite.
Cite this record
ConductScience Library. Are we there yet? CAR-T therapy in multiple myeloma. Papers, record 39558776. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39558776
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Multiple Myeloma | Major topic |
| Immunotherapy, Adoptive | Major topic |
| Receptors, Chimeric Antigen | Major topic |
| Humans | |
| B-Cell Maturation Antigen | |
| T-Lymphocytes |
Source PubMed
References98
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35287669 | Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells. | J Transl Med | 2022 | https://conductscience.org/library/papers/35287669 | PubMed |
| 2 | 35105265 | A combination of humanized anti-BCMA and murine anti-CD38 CAR-T cell therapy in patients with relapsed or refractory multiple myeloma. | Leuk Lymphoma | 2022 | https://conductscience.org/library/papers/35105265 | PubMed |
| 3 | 37414060 | Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study. | Lancet Oncol | 2023 | https://conductscience.org/library/papers/37414060 | PubMed |
| 4 | 37339964 | Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma. | Nat Commun | 2023 | https://conductscience.org/library/papers/37339964 | PubMed |
| 5 | 37591876 | Long-term outcomes of allogeneic stem cell transplant in multiple myeloma. | Blood Cancer J | 2023 | https://conductscience.org/library/papers/37591876 | PubMed |
| 6 | 35125241 | Harnessing natural killer cells for the treatment of multiple myeloma. | Semin Oncol | 2022 | https://conductscience.org/library/papers/35125241 | PubMed |
| 7 | 34175021 | Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. | Lancet | 2021 | https://conductscience.org/library/papers/34175021 | PubMed |
| 8 | 25939063 | 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. | Nat Med | 2015 | https://conductscience.org/library/papers/25939063 | PubMed |
| 9 | 37844355 | Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma. | Biomed Pharmacother | 2023 | https://conductscience.org/library/papers/37844355 | PubMed |
| 10 | 37653344 | Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma. | Nat Med | 2023 | https://conductscience.org/library/papers/37653344 | PubMed |
| 11 | 36446823 | Quadruple gene-engineered natural killer cells enable multi-antigen targeting for durable antitumor activity against multiple myeloma. | Nat Commun | 2022 | https://conductscience.org/library/papers/36446823 | PubMed |
| 12 | 29435173 | CRISPR knock out of programmed cell death protein 1 enhances anti-tumor activity of cytotoxic T lymphocytes. | Oncotarget | 2018 | https://conductscience.org/library/papers/29435173 | PubMed |
| 13 | 35702871 | Bispecific T-cell engagers for treatment of multiple myeloma. | Am J Hematol | 2023 | https://conductscience.org/library/papers/35702871 | PubMed |
| 14 | 36064867 | Potential solutions for manufacture of CAR T cells in cancer immunotherapy. | Nat Commun | 2022 | https://conductscience.org/library/papers/36064867 | PubMed |
| 15 | 31900462 | 'Off-the-shelf' allogeneic CAR T cells: development and challenges. | Nat Rev Drug Discov | 2020 | https://conductscience.org/library/papers/31900462 | PubMed |
| 16 | 36881785 | Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase Ⅱ Trial. | J Clin Oncol | 2023 | https://conductscience.org/library/papers/36881785 | PubMed |
| 17 | 33499253 | Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/33499253 | PubMed |
| 18 | 34445701 | CAR T-Cell Therapy in Hematological Malignancies. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34445701 | PubMed |
| 19 | 30718503 | Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma. | Blood Cancer J | 2019 | https://conductscience.org/library/papers/30718503 | PubMed |
| 20 | 32034142 | CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide. | Nat Commun | 2020 | https://conductscience.org/library/papers/32034142 | PubMed |
Cited by4
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42780650 | A 3D engineered multiple myeloma niche for evaluating CAR T cell therapy. | Front Bioeng Biotechnol | 2026 | https://conductscience.org/library/papers/42780650 | PubMed |
| 41428622 | 2025 Update of Cellular Immunotherapy for Plasma Cell Disorders. | Turk J Haematol | 2026 | https://conductscience.org/library/papers/41428622 | PubMed |
| 41410870 | Pomalidomide enhances CAR-T cell therapeutic efficacy and remodels immune microenvironment in lymphoid malignancies. | Cancer Immunol Immunother | 2025 | https://conductscience.org/library/papers/41410870 | PubMed |
| 39558776 | Are we there yet? CAR-T therapy in multiple myeloma. | Br J Haematol | 2024 | https://conductscience.org/library/papers/39558776 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| FCRL5 | 83416 | PubTator's text mining | https://conductscience.org/library/genes/83416 | NCBI Gene |
| GPRC5D | 55507 | PubTator's text mining | https://conductscience.org/library/genes/55507 | NCBI Gene |
| SLAMF7 | 57823 | PubTator's text mining | https://conductscience.org/library/genes/57823 | NCBI Gene |
| TNFRSF17 | 608 | PubTator's text mining | https://conductscience.org/library/genes/608 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39558776
GET https://conductscience.org/api/papers/v1/39558776/references?page=2